#United Kingdom #Cardiovascular Disease #Galway #Global Heart Hub #IPEC2

Understanding the Delay in Heart Care for Women

Recent research conducted by Global Heart Hub sheds light on a critical issue within women's health—specifically the worrying trend of women delaying or dismissing their heart symptoms. Despite heart disease being the leading cause of death among women globally, many continue to prioritize others over seeking necessary medical help. This article summarizes the patient-led research findings presented at the European Society of Cardiology's ACNAP Congress 2026, emphasizing the barriers women face in recognizing and addressing cardiovascular disease (CVD).

Key Findings from the Research

The study, known as IPEC2 (Insights on Patient Experiences with Cardiovascular Disease), gathered qualitative data from women across eight countries. It involved women diagnosed with conditions such as elevated low-density lipoprotein cholesterol (LDL-C), heart valve disease, and cardiomyopathy. The research aimed to understand their experiences, awareness of symptoms, and the barriers they encounter in receiving timely diagnosis and treatment.

Initial findings revealed that women often find their symptoms misdiagnosed as anxiety or other non-cardiac conditions. Many participants reported feeling dismissed during their healthcare visits, with healthcare professionals occasionally labeling them as “too young” or “not the type” for CVD. This bias highlights a crucial gap in medical understanding, where women’s unique symptoms are overshadowed by traditional male-centric definitions of cardiovascular health.

Impacts of Delay on Women’s Health

The consequences of these delays can be dire. With CVD being a leading cause of death among women, the results of the IPEC2 study illustrate the pressing need for more accurate diagnoses and better awareness about women's health issues. It's essential to ensure that healthcare providers recognize symptoms that may differ from the gender norms surrounding heart disease. The study emphasizes the importance of “thinking heart first” for women everywhere, encouraging healthcare professionals to adopt a more inclusive approach.

Professor Vijay Kunadian, a member of the Steering Committee for IPEC2, affirmed: “We now have incredible therapies for high LDL-C levels. However, if women do not receive timely diagnoses, they cannot access treatment effectively.” The findings reflect a dire situation where women often receive treatment only after severe events such as heart attacks or strokes, which drastically reduces their chances of optimal recovery.

The Role of Education and Awareness

The study underscores the need for enhanced patient education regarding heart disease. Many women are unaware of the variety of symptoms that may signal cardiovascular issues; therefore, greater emphasis on symptom recognition can foster early detection. Educational initiatives targeted at both women and healthcare providers are necessary to bridge the knowledge gap. Furthermore, acknowledging and addressing the biases that influence diagnosis is vital for improvement in patient outcomes.

The Future of Cardiovascular Care for Women

IPEC2 aims to strengthen our understanding of women's experiences with CVD and make strong recommendations for improving patient care. As mentioned by Neil Johnson, Executive Director of Global Heart Hub, “We need to make heart health a priority for every woman.” Such advocacy can lead to enhanced recognition of symptoms and a firmer commitment to equitable patient care, allowing women to receive the treatment they need when they need it.

In conclusion, addressing these deeply rooted biases and gaps in healthcare response is not merely a healthcare issue, but a societal challenge. By amplifying women's voices and experiences in cardiovascular care, we take a crucial step towards saving lives and ensuring healthier futures.

For those interested in further information, the IPEC2 initiative can be explored in more detail at Global Heart Hub.

About Global Heart Hub

Established in 2019 and based in Ireland, Global Heart Hub serves as a powerful voice for the 150+ patient organisations it unites globally. Its aim is to create a collective dialogue regarding heart disease and its many impacts on individuals and communities. With support from prominent pharmaceutical companies, including Amgen Inc., Daiichi Sankyo Europe, and Novartis Pharmaceuticals Corporation, Global Heart Hub continues to advocate for improved care and outcomes in cardiovascular health.